Duvelisib
- Generic Name
- Duvelisib
- Brand Names
- Copiktra
- Drug Type
- Small Molecule
- Chemical Formula
- C22H17ClN6O
- CAS Number
- 1201438-56-3
- Unique Ingredient Identifier
- 610V23S0JI
- Background
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of bo...
- Indication
Duvelisib is indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients who have trialed at least two prior therapies.
- Associated Conditions
- Refractory Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Small Lymphocytic Lymphoma
- Associated Therapies
- -
Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 7
- Registration Number
- NCT02598570
- Locations
- 🇯🇵
Site Reference ID/Investigator# 141595, Fukuoka, Japan
🇯🇵Site Reference ID/Investigator# 141826, Aichi, Japan
🇯🇵Site Reference ID/Investigator# 141594, Tokyo, Japan
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- SecuraBio
- Registration Number
- NCT02576275
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 55
- Registration Number
- NCT02391545
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 13
- Registration Number
- NCT02204982
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 319
- Registration Number
- NCT02004522
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 129
- Registration Number
- NCT01882803
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.